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88 Poster Session Im2. Patients undergoing unrelated donor transplants received an-
tithymocyte globulin, 30 mg/kg, on days -2, -1, and 16. The last
8 Busulfan doses were adjusted to achieve areas under the concen-
tration time curve of 600 – 900 micromol.min/liter. Family donor
transplant recipients (n5 9), received Cyclosporine/Methotrexate/
Leukovorin as GVHD prophylaxis; unrelated donor transplant re-
cipients (n 5 19) received Cyclosporine/Steroid prophylaxis; one
patient underwent syngeneic BMT. With a minimum of 12 months
and a median of 66 months follow-up, 19 of the 29 (66%) survive
event-free and 22 of the 29 (76%) survive overall. Five patients re-
lapsed. Three patients in relapse at the time of BMT achieved CR
but relapsed at 5, 5 and 6 months. Two patients with Ph1 ALL re-
lapsed 15 and 26 months after BMT and survive event-free 421 and
391 months, respectively, after 2nd transplants with TBI-contain-
ing regimens. One patient with AML in CR2 suffered rejection of
an unrelated cord blood but survives event-free 631 months after
autologous stem cell infusion. Four died of transplant-related com-
plications (multi-organ failure, disseminated adenovirus infection,
enterococcal sepsis, and hemolytic-uremic syndrome with Aspergil-
losis). Toxicity was considerable and included mucositis requiring
parental nutrition (29 of 29), hemolytic uremic syndrome (n 5 5),
pulmonary hemorrhage (n5 3), veno-occlusive disease (n5 3), sei-
zures (n 5 1).
Our data suggest that although this is a moderately toxic regimen,
Busulfan/Melphalan shows promising activity as preparative ther-
apy for infants and very young children with leukemias, avoids total
body irradiation, and produces outcomes similar to those previously
reported for patients in this age group.
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Leukocyte adhesion deficiency (LAD) is a rare disorder charac-
terized by the congenital absence of CD18 resulting in the loss of
expression of leukocyte CD11/CD18 integrins on myeloid cells
with resultant life threatening infections. Hematopoietic stem cell
transplantation currently provides the only available cure for this
disorder. Although there have been reports of some success in trans-
plantation using related family member donors or unrelated mar-
row donors with either myeloablative or non-myeloablative
prepartative regimens, there is little experience with the use of um-
bilical cord SCT. We present here the first report of a patient trans-
planted with unrelated donor cord blood (UCB) for severe LAD
type 1. The patient was diagnosed at 2 months of age when he pre-
sented with failure to thrive, fever, mastoiditis, and lethargy. Labo-
ratory evaluation revealed a WBC of 165,000 (predominantly
neutrophils) and flow cytometry documented the absence of neutro-
phil expression of CD11b and CD18. He was treated with antibi-
otics and surgical drainage of his mastoid bone. Since no family
donors were identified, and given the need to proceed with trans-
plant expeditiously and to minimize the risk of GVHD, unrelated
donor cord blood transplant was pursued using a non-myeloablative
preparative regimen. A large (16.5  107 TNC/kg and 9.5  105
CD34 cell/kg) 10 of 10 antigen matched unrelated donor cord
blood unit was identified. The preparative regimen included Cam-
path-1H3 (10 mg/d iv days -21 to – 19), fludarabine (30 mg/m2/d iv
days -8 to -4) and melphalan (140 mg/m2 iv day -3). GVHD prophy-
laxis consisted of CSA 1 mycophenolate. He engrafted and was
transfusion independent by day 16. He had no evidence of
GVHD, and donor-host studies revealed 40% donor on day 15.
His donor chimerism fell to 16% by STR on day 41 confirmed
100% recipient by VNTR. His cyclosporine was discontinued
and an extensive viral screen showed no evidence of CMV, EBV,
HHV6, adenovirus, or Hepatitis B. Over the next several months,
his donor chimerism slowly rose to 48% where it has remained sta-
ble for the past 7 months with 44% of his granulocytes positive for
CD11b/CD18. He remains clinically well off all immune suppres-
sion 13 months post-transplant with normal growth and develop-
ment.
Conclusion: UCB is a viable source of stem cells for LAD
patients.238
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Background and Objective: A novel reduced intensity condi-
tioning (RIC) regimen was used for hematopoietic stem cell trans-
plantation (HSCT) in childhood non-malignant disorders in an
effort to reduce regimen related organ toxicities and the incidence
and severity of graft-versus-host disease (GVHD). Recipient immu-
nosuppression was used to achieve donor cell engraftment and post-
transplant monitoring included infection surveillance until immune
reconstitution. This retrospective study evaluates duration of hospi-
talization within the first 100 days following HSCT in RIC recipi-
ents. Methods: Thirty patients (7 months to 17 years) with
hemoglobinopathies (4), bone marrow failure (7), immune dysfunc-
tion (11), metabolic disorders (7), and mitochondrial myopathy (1)
underwent HSCT following conditioning with alemtuzumab (48
mg; day -21 to -19), fludarabine (150 mg/m2; day -8 to -4), and mel-
phalan (140 mg/m2 [24] or 70 mg/m2 [6] on day -3). Doses were
lower for patients\10 kg. Stem cell sources included peripheral
blood (PBSC) (4), cord cells (UCB) (5), and bone marrow (BM)
(21). Seven patients (5 UCB; 2 BM/PBSC) received 1–2 antigen
mismatched products. GVHD prophylaxis included a calcineurin
inhibitor, methotrexate (except in 4 UCB transplants) and methyl
prednisolone. Results: Durations of hospitalization in the first
100 days is shown in Table 1; all had donor cell engraftment.
Median number of in-patient days was 22.5 for the group and
was similar for unrelated and related HSCT (Table 1). UCB re-
cipients stayed longer. Eight patients were hospitalized for .30
days (3 unrelated and 1 related BM, 4 mismatched UCB) for he-
molysis (1), organ failure (3), GVHD (3) and infection. Infections
which required hospitalization included bacteria (6), non-CMV
viruses (3), CMV reactivation (3), CMV disease (2), and C. diffi-
cile (4). Three patients died before day 100 of GVHD (1), pro-
gressive disease (1), and infection (1). Conclusions: Recipients
of this RIC regimen had an acceptable duration of hospitalization
in the first 100 days post-transplant. Infectious complications and
GVHD accounted for prolonged hospitalization (.30 days) in the
majority of patients.Table 1. In-patient stay in the first 100 days following HSCT
Median days of
Recipient Details
(number)
hospitalization
(range)
Mean days of
hospitalizationTotal (30) 22.5 (12–88) 29.5
Alive beyond 100 days
(27)22 (12–84) 27Died prior to day 100 (3) 51 (18–88) 51.7
UCB (all unrelated,
mismatched) (5)46 (21–88) 50.3BM 1 PBSC recipients
(25)21.5 (12–84) 26.3Unrelated BM or PBSC
(HLA-matched) (11)27 (14–84) 32.1Unrelated BM or PBSC
(mismatched) (2)20 (15–25) 20Matched related donors
(12)21 (12–42) 21.8
